

HTR2A Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP17879c**Specification****HTR2A Antibody (Center) Blocking Peptide -
Product Information**Primary Accession [P28223](#)**HTR2A Antibody (Center) Blocking Peptide -
Additional Information****Gene ID** 3356**Other Names**5-hydroxytryptamine receptor 2A, 5-HT-2,
5-HT-2A, Serotonin receptor 2A, HTR2A,
HTR2**Format**Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.**Storage**Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.**Precautions**This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.**HTR2A Antibody (Center) Blocking Peptide -
Protein Information****Name** HTR2A**Synonyms** HTR2**Function**G-protein coupled receptor for
5-hydroxytryptamine (serotonin)
(PubMed:<a href="http://www.uniprot.org/c
itations/1330647"
target="_blank">1330647,
PubMed:<a href="http://www.uniprot.org/ci
tations/18703043"**HTR2A Antibody (Center) Blocking Peptide
- Background**

This gene encodes one of the receptors for serotonin, a neurotransmitter with many roles. Mutations in this gene are associated with susceptibility to schizophrenia and obsessive-compulsive disorder, and are also associated with response to the antidepressant citalopram in patients with major depressive disorder (MDD). MDD patients who also have a mutation in intron 2 of this gene show a significantly reduced response to citalopram as this antidepressant downregulates expression of this gene. Multiple transcript variants encoding different isoforms have been found for this gene.

**HTR2A Antibody (Center) Blocking Peptide
- References**

Blaya, C., et al. Neurosci. Lett. 485(1):11-15(2010)
Klein, A.B., et al. J. Cereb. Blood Flow Metab. 30 (11), E1-E7 (2010)
Borrito-Escuela, D.O., et al. Biochem. Biophys. Res. Commun. 401(4):605-610(2010)
Terrazzino, S., et al. Headache (2010) In press
Kapelski, P., et al. Psychiatr. Pol. 44(2):197-206(2010)

target="_blank">18703043, PubMed:19057895). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) (PubMed:28129538). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors (PubMed:28129538). Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways (PubMed:28129538). Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores (PubMed:18703043, PubMed:28129538). Affects neural activity, perception, cognition and mood (PubMed:18297054). Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.

Cellular Location

Cell membrane; Multi-pass membrane protein. Cell projection, dendrite {ECO:0000250|UniProtKB:P35363}. Cell projection, axon {ECO:0000250|UniProtKB:P14842}. Cytoplasmic vesicle {ECO:0000250|UniProtKB:P14842}. Membrane, caveola {ECO:0000250|UniProtKB:P14842}. Cell junction, synapse, presynapse

{ECO:0000250|UniProtKB:P14842}

Tissue Location

Detected in brain cortex (at protein level).

Detected in blood platelets.

**HTR2A Antibody (Center) Blocking Peptide
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)